Preclinical Data Supports TPC-026 for Chronic Metabolic Disorders
TETRAPHARM, a Copenhagen-based biopharmaceutical company focused on neuroscience, psychiatry, and metabolic disorders, today announced promising preclinical data for TPC-026, a novel investigational compound being developed for...
